The performance of two commercial real-time PCR kits for the detection of Mycoplasma genitalium was evaluated in comparison to an in-house real-time PCR assay. Concordances of 96% and 93% were found for the TIB MOLBIOL and the Diagenode assays, respectively, compared to the results of the in-house assay.
Diagenode, Belgium) using the MagNa Pure liquid chromatography (LC) DNA isolation kit I on the MagNa Pure LC extraction system (Roche Diagnostics, France) according to the manufacturer's instructions. The elution volume was 100 l. The limit of the in-house assay detection was unchanged in the presence of the Dia-EIC (data not shown).
The 54 M. genitalium-positive DNA extracts were obtained from 31 women and 23 men and included 31 vaginal and 5 urethral samples and 18 male urine samples. The 50 M. genitaliumnegative DNA extracts were collected from 34 women and 16 men and included 34 vaginal and 2 urethral samples and 14 male urine samples. All of the tests were performed on the same DNA extracts, which had been stored at Ϫ80°C and thawed. The 104 DNA extracts were reevaluated with the in-house real-time PCR assay using two real-time PCR instruments: the LC480 and the cobas z 480 analyzer. The 20-l PCR mixture consisted of 0.3 M each (8) , and the data analysis was performed using the absolute-quantification fit point method with the filter combination with an excitation wavelength range of 483 to 533 nm for the LightCycler 480 software or with the filter combination with a range of 465 to 510 nm for the UDF software. The experimenter was blinded to the results of the different assays. Two commercial M. genitalium detection kits, the TIB MOLBIOL LightMix kit Mycoplasma genitalium targeting a 224-bp gap gene fragment and the Diagenode Mycoplasma genitalium real-time PCR kit (DIA-MG-050 vs2) targeting a 251-bp mg219 gene fragment, were evaluated in comparison to the inhouse real-time PCR using the cobas z 480 analyzer. PCR mixtures of 25 l were prepared using the LightCycler 480 probe master mix and 5 l of template DNA according to each manufacturer's instructions. The data were analyzed with the UDF software using the absolute-quantification fit point method and required the use of a color compensation file generated by the TIB MOLBIOL LightMix universal color compensation 530/640/690 or the Diagenode color compensation set [DIA-DAF(Lc480)-005]. The filter combinations used for M. genitalium detection were that with a range of 498 to 645 nm for the LightMix kit and that with a range of 465 to 510 nm for the Diagenode kit. The filter combinations were that with a range of 498 to 700 nm for the internal control LightMix kit and that with a range of 498 to 580 nm for Universal Internal Control Diagenode (DIA-UIC-050).
Comparisons were made using McNemar's and one-way analysis of variance (ANOVA) tests for qualitative and quantitative variables, respectively. The kappa statistic () was used to evaluate the agreement between the commercial kits and the in-house PCR results. The clinical sensitivity and specificity of the commercial tests were calculated on the basis of the results obtained from the in-house PCR assay that we used as a proxy for a gold standard for these patients. Statistical analysis used the biostaTGV website (marne.u707.jussieu.fr/biostatgv/). A P value of Ͻ0.05 was considered statistically significant.
Among the 54 M. genitalium-positive and 50 M. genitaliumnegative DNA extracts, one extract (no. 1; Table 1 ) provided a discrepant result, which was positive with the LC480 analyzer and negative with the cobas z 480 analyzer. However, there was no significant difference in the sensitivity and the specificity of the cobas z 480 (sensitivity of 98.1%, 95% confidence interval [CI] of 90.2 to 99.7; specificity of 100%, 95% CI of 92.9 to 100) compared to those of the LC480. This discrepant result could be considered a false-negative result on cobas z 480 because extract no. 1 was M. genitalium positive 3 times out of 4. Furthermore, the cycle threshold (C T ) values indicated a sample with a low M. genitalium DNA load, and the z480 false-negative result could likely to be due to a sampling error (Table 1) .
Both commercial kits accurately detected the 50 negative specimens and 46 of the 54 positive specimens (Table 2) . For each kit, the internal control was properly amplified in all extracts. Eight extracts provided discrepant results: three were negative according to both commercial tests, one was negative with the LightMix kit only, and four were negative with the Diagenode kit only. C T values for each of the assays in these 8 discrepant samples (no. 2 to 9) are listed in Table 1 . The clinical sensitivity was 92.6% for the LightMix kit and 87% for the Diagenode kit. The clinical specificity was 100% for both commercial kits (Table 2 ). There was no statistically significant difference between the clinical sensitivity and specificity of each of the commercial assays compared to those of the in-house method (P Ͼ 0.05). We found a concordance of 96% ( ϭ 0.92; 95% CI, 0.905 to 0.985) for the LightMix kit and of 93% ( ϭ 0.86; 95% CI, 0.867 to 0.967) for the Diagenode kit, indicating a very good agreement between these kits and the inhouse PCR assay. The mean C T Ϯ standard deviation (SD) values of 33.8 Ϯ 3.9, 34.5 Ϯ 4.0, and 33.8 Ϯ 3.5, respectively, obtained from the in-house PCR, LightMix, and Diagenode kits on cobas z 480, were not significantly different (P Ͼ 0.05).
In conclusion, the LC480 instrument and the cobas z 480 analyzer used with the UDF software presented identical performances when applied to the M. genitalium in-house real-time PCR assay. Both of the commercial kits allowed similar sensitive and specific results when used with the LightCycler 480 probe master mix and the cobas z 480 instrument, validated by the use of an internal amplification control.
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